184 related articles for article (PubMed ID: 26510854)
1. Inhibiting the PI3K signaling pathway: buparlisib as a new targeted option in breast carcinoma.
Estévez LG; García E; Hidalgo M
Clin Transl Oncol; 2016 Jun; 18(6):541-9. PubMed ID: 26510854
[TBL] [Abstract][Full Text] [Related]
2. Buparlisib , an oral pan-PI3K inhibitor for the treatment of breast cancer.
Geuna E; Milani A; Martinello R; Aversa C; Valabrega G; Scaltriti M; Montemurro F
Expert Opin Investig Drugs; 2015 Mar; 24(3):421-31. PubMed ID: 25645727
[TBL] [Abstract][Full Text] [Related]
3. Buparlisib in breast cancer.
Sirohi B; Rastogi S; Dawood S
Future Oncol; 2015; 11(10):1463-70. PubMed ID: 25963424
[TBL] [Abstract][Full Text] [Related]
4. Benefits versus risk profile of buparlisib for the treatment of breast cancer.
Patsouris A; Augereau P; Frenel JS; Robert M; Gourmelon C; Bourbouloux E; Berton-Rigaud D; Chevalier LM; Campone M
Expert Opin Drug Saf; 2019 Jul; 18(7):553-562. PubMed ID: 31159599
[No Abstract] [Full Text] [Related]
5. Phase I Study of the Pan-PI3K Inhibitor Buparlisib in Adult Chinese Patients with Advanced Solid Tumors.
Wu YL; Zhang LI; Trandafir L; Dong T; Duval V; Hazell K; Xu B
Anticancer Res; 2016 Nov; 36(11):6185-6194. PubMed ID: 27793950
[TBL] [Abstract][Full Text] [Related]
6. Treatment effect of buparlisib, cetuximab and irradiation in wild-type or PI3KCA-mutated head and neck cancer cell lines.
Lattanzio L; Tonissi F; Monteverde M; Vivenza D; Russi E; Milano G; Merlano M; Lo Nigro C
Invest New Drugs; 2015 Apr; 33(2):310-20. PubMed ID: 25603975
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of In Vitro Activity of the Class I PI3K Inhibitor Buparlisib (BKM120) in Pediatric Bone and Soft Tissue Sarcomas.
Anderson JL; Park A; Akiyama R; Tap WD; Denny CT; Federman N
PLoS One; 2015; 10(9):e0133610. PubMed ID: 26402468
[TBL] [Abstract][Full Text] [Related]
8. Targeting survival and cell trafficking in multiple myeloma and Waldenstrom macroglobulinemia using pan-class I PI3K inhibitor, buparlisib.
Sahin I; Azab F; Mishima Y; Moschetta M; Tsang B; Glavey SV; Manier S; Zhang Y; Sacco A; Roccaro AM; Azab AK; Ghobrial IM
Am J Hematol; 2014 Nov; 89(11):1030-6. PubMed ID: 25060991
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of buparlisib in treating breast cancer.
Robert M; Frenel JS; Bourbouloux E; Berton Rigaud D; Patsouris A; Augereau P; Gourmelon C; Campone M
Expert Opin Pharmacother; 2017 Dec; 18(18):2007-2016. PubMed ID: 29169282
[TBL] [Abstract][Full Text] [Related]
10. Dual inhibition of PI3K and mTOR mitigates compensatory AKT activation and improves tamoxifen response in breast cancer.
Chen X; Zhao M; Hao M; Sun X; Wang J; Mao Y; Zu L; Liu J; Shen Y; Wang J; Shen K
Mol Cancer Res; 2013 Oct; 11(10):1269-78. PubMed ID: 23814023
[TBL] [Abstract][Full Text] [Related]
11. Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer: Results from the Phase II BASALT-1 Study.
Vansteenkiste JF; Canon JL; De Braud F; Grossi F; De Pas T; Gray JE; Su WC; Felip E; Yoshioka H; Gridelli C; Dy GK; Thongprasert S; Reck M; Aimone P; Vidam GA; Roussou P; Wang YA; Di Tomaso E; Soria JC
J Thorac Oncol; 2015 Sep; 10(9):1319-1327. PubMed ID: 26098748
[TBL] [Abstract][Full Text] [Related]
12. Mass Spectrometry-Based Proteomics Reveals Potential Roles of NEK9 and MAP2K4 in Resistance to PI3K Inhibition in Triple-Negative Breast Cancers.
Mundt F; Rajput S; Li S; Ruggles KV; Mooradian AD; Mertins P; Gillette MA; Krug K; Guo Z; Hoog J; Erdmann-Gilmore P; Primeau T; Huang S; Edwards DP; Wang X; Wang X; Kawaler E; Mani DR; Clauser KR; Gao F; Luo J; Davies SR; Johnson GL; Huang KL; Yoon CJ; Ding L; Fenyö D; Ellis MJ; Townsend RR; Held JM; Carr SA; Ma CX
Cancer Res; 2018 May; 78(10):2732-2746. PubMed ID: 29472518
[TBL] [Abstract][Full Text] [Related]
13. Roles of phosphatidylinositol-3-kinases signaling pathway in inflammation-related cancer: Impact of rs10889677 variant and buparlisib in colitis-associated cancer.
Razali NN; Raja Ali RA; Muhammad Nawawi KN; Yahaya A; Mohd Rathi ND; Mokhtar NM
World J Gastroenterol; 2023 Oct; 29(40):5543-5556. PubMed ID: 37970476
[TBL] [Abstract][Full Text] [Related]
14. A phase 2 trial of buparlisib in patients with platinum-resistant metastatic urothelial carcinoma.
McPherson V; Reardon B; Bhayankara A; Scott SN; Boyd ME; Garcia-Grossman IR; Regazzi AM; McCoy AS; Kim PH; Al-Ahmadie H; Ostrovnaya I; Roth AJ; Farooki A; Berger MF; Rosenberg JE; Solit DB; Van Allen E; Milowsky MI; Bajorin DF; Iyer G
Cancer; 2020 Oct; 126(20):4532-4544. PubMed ID: 32767682
[TBL] [Abstract][Full Text] [Related]
15. RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer.
Serra V; Eichhorn PJ; García-García C; Ibrahim YH; Prudkin L; Sánchez G; Rodríguez O; Antón P; Parra JL; Marlow S; Scaltriti M; Pérez-Garcia J; Prat A; Arribas J; Hahn WC; Kim SY; Baselga J
J Clin Invest; 2013 Jun; 123(6):2551-63. PubMed ID: 23635776
[TBL] [Abstract][Full Text] [Related]
16. Disruption of follicular dendritic cells-follicular lymphoma cross-talk by the pan-PI3K inhibitor BKM120 (Buparlisib).
Matas-Céspedes A; Rodriguez V; Kalko SG; Vidal-Crespo A; Rosich L; Casserras T; Balsas P; Villamor N; Giné E; Campo E; Roué G; López-Guillermo A; Colomer D; Pérez-Galán P
Clin Cancer Res; 2014 Jul; 20(13):3458-71. PubMed ID: 24799524
[TBL] [Abstract][Full Text] [Related]
17. The PI3K inhibitor buparlisib suppresses osteoclast formation and tumour cell growth in bone metastasis of lung cancer, as evidenced by multimodality molecular imaging.
Wang S; Niu X; Bao X; Wang Q; Zhang J; Lu S; Wang Y; Xu L; Wang M; Zhang J
Oncol Rep; 2019 May; 41(5):2636-2646. PubMed ID: 30896825
[TBL] [Abstract][Full Text] [Related]
18. Which Is the Most Appropriate PI3K Inhibitor for Breast Cancer Patients with or without PIK3CA Status Mutant? A Systematic Review and Network Meta-Analysis.
Wang S; Liu M; Lian S; Liu N; Zhang G; Zhao Q; Zhang Y; Jian L
Biomed Res Int; 2020; 2020():7451576. PubMed ID: 33376736
[TBL] [Abstract][Full Text] [Related]
19. Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.
Rodon J; Braña I; Siu LL; De Jonge MJ; Homji N; Mills D; Di Tomaso E; Sarr C; Trandafir L; Massacesi C; Eskens F; Bendell JC
Invest New Drugs; 2014 Aug; 32(4):670-81. PubMed ID: 24652201
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of PI3K pathway using BKM120 intensified the chemo-sensitivity of breast cancer cells to arsenic trioxide (ATO).
Alipour F; Riyahi N; Safaroghli-Azar A; Sari S; Zandi Z; Bashash D
Int J Biochem Cell Biol; 2019 Nov; 116():105615. PubMed ID: 31539632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
